Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
Myung‐Ju Ahn(Sungkyunkwan University), Maen Hussein(Sarah Cannon), Zhongwu Lai(AstraZeneca (United States)), Dolores Mendoza Oliva(Institute for Scientific and Technological Research), Igor Bondarenko(Dnipro State Medical University), Ingel Demedts(AZ Delta), Rajnish Nagarkar(HCG Cancer Centre), Nikolay Kislov(GOUZ YaO "Solovyov NV Clinical Emergency Hospital"), Byoung Chul Cho(Yonsei University), Gabriella Gálffy, Xiaojin Shi, Helen Mann(AstraZeneca (United Kingdom)), Ewa Kalinka‐Warzocha(Apple (Israel)), Shunichi Sugawara(Sendai Kousei Hospital), Ross Stewart(AstraZeneca (United Kingdom)), Steven Gans, Byoung Yong Shim(The Catholic University of Korea St. Vincent's Hospital)
Cited by 11
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k